A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
74actual
Sites
41
Countries
Argentina, Australia, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-12 | actual | When the study began enrolling |
| Primary completion | 2024-08-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-23 | actual | When this record first appeared on the registry |
| Results posted | 2025-09-10 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-09-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lupus Erythematosus, Discoid
- Lupus Erythematosus, Subacute Cutaneous
Interventions
- Drug: Deucravacitinib
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage Change From Baseline in CLASI Activity Score at Week 16
measured From first dose to Week 16 (approximately 16 weeks)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2022-04-15 · 12.5 MB · Prot_SAP_000.pdf
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed